BNP improves outcomes in evaluation of dyspnoeaBMJ 2004; 328 doi: http://dx.doi.org/10.1136/bmj.328.7451.0-f (Published 27 May 2004) Cite this as: BMJ 2004;328:0-f
Question Does use of the test for B-type natriuretic peptide (BNP) in the diagnosis of acute dyspnoea improve patients' outcomes?
Synopsis Too often, new tests are introduced without a careful examination of their effect on patient oriented outcomes. Accuracy alone is not reason enough to adopt a test; a more important reason is that its use helps patients live better or longer lives. We should also know whether is adds or reduces cost. There is previous convincing evidence that B-type natriuretic peptide is accurate in diagnosing heart failure in patients presenting with acute dyspnoea (N Engl J Med 2002;106:416-22). This latest randomised controlled trial (single blinded) study is the first to look at the larger …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial